Free tool
FAERS Monitor: Inomax
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020845 or its brand name (Inomax, Nitric Oxide). Reports on generic versions are filed under their own applications.
Reports
2,910
Serious
2,770
95% of reports
Hospitalization
726
Death reported
1,302
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product use issue377
- death364
- off label use342
- drug ineffective329
- product use in unapproved indication211
- condition aggravated200
- oxygen saturation decreased195
- respiratory failure152
- pulmonary hypertension151
- hypotension138
- hypoxia130
- cardiac arrest111
- drug ineffective for unapproved indication84
- pulmonary haemorrhage83
- therapy non-responder78
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 18 |
| 2006 | 43 |
| 2007 | 77 |
| 2008 | 40 |
| 2009 | 30 |
| 2010 | 40 |
| 2011 | 79 |
| 2012 | 39 |
| 2013 | 49 |
| 2014 | 55 |
| 2015 | 52 |
| 2016 | 116 |
| 2017 | 140 |
| 2018 | 127 |
| 2019 | 142 |
| 2020 | 211 |
| 2021 | 235 |
| 2022 | 274 |
| 2023 | 263 |
| 2024 | 357 |
| 2025 | 315 |
| 2026 | 201 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,249 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pulmonary haemorrhageSignal | 83 | 77.5 | 62.6 | 6,127 |
| pulmonary hypertensionSignal | 151 | 52.8 | 45.1 | 7,568 |
| hypoxiaSignal | 130 | 26.8 | 22.6 | 3,194 |
| oxygen saturation decreasedSignal | 195 | 25.2 | 22.0 | 4,497 |
| respiratory failureSignal | 152 | 15.1 | 12.9 | 1,989 |
| product use issueSignal | 377 | 14.5 | 13.2 | 4,768 |
| therapy non-responderSignal | 78 | 12.6 | 10.1 | 819 |
| drug ineffective for unapproved indicationSignal | 84 | 11.1 | 9.0 | 761 |
| cardiac arrestSignal | 111 | 9.7 | 8.1 | 863 |
| product use in unapproved indicationSignal | 211 | 6.2 | 5.4 | 916 |
| hypotensionSignal | 138 | 5.0 | 4.2 | 438 |
| condition aggravatedSignal | 200 | 4.8 | 4.2 | 598 |
| deathSignal | 364 | 3.1 | 2.8 | 522 |
| off label useSignal | 342 | 2.8 | 2.6 | 418 |
| drug ineffective | 329 | 1.8 | 1.6 | 125 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.